CN110448551A - Dihydroqinghaosu is preparing the application in anti-angiogenic medicaments - Google Patents
Dihydroqinghaosu is preparing the application in anti-angiogenic medicaments Download PDFInfo
- Publication number
- CN110448551A CN110448551A CN201910785570.9A CN201910785570A CN110448551A CN 110448551 A CN110448551 A CN 110448551A CN 201910785570 A CN201910785570 A CN 201910785570A CN 110448551 A CN110448551 A CN 110448551A
- Authority
- CN
- China
- Prior art keywords
- nmr
- cdcl
- alkyl
- independently
- 300mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 title claims abstract description 15
- 229960002521 artenimol Drugs 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 230000001772 anti-angiogenic effect Effects 0.000 title claims abstract description 5
- -1 amino, hydroxyl Chemical group 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 6
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000001924 fatty-acyl group Chemical group 0.000 claims 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 190
- 238000005160 1H NMR spectroscopy Methods 0.000 description 50
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 45
- 238000004896 high resolution mass spectrometry Methods 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002002 slurry Substances 0.000 description 8
- 230000003527 anti-angiogenesis Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 229930101531 artemisinin Natural products 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229930183339 qinghaosu Natural products 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- JAAIPIWKKXCNOC-UHFFFAOYSA-N 1h-tetrazol-1-ium-5-thiolate Chemical compound SC1=NN=NN1 JAAIPIWKKXCNOC-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- ZPOLNCDBPYJDSE-UHFFFAOYSA-N 3-[4-[bis(2-chloroethyl)amino]phenyl]-2-formamidopropanoic acid Chemical compound O=CNC(C(=O)O)CC1=CC=C(N(CCCl)CCCl)C=C1 ZPOLNCDBPYJDSE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- WZUUZPAYWFIBDF-UHFFFAOYSA-N 5-amino-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound NC1=NNC(S)=N1 WZUUZPAYWFIBDF-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N 5-methyl-2h-tetrazole Chemical compound CC=1N=NNN=1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 150000007980 azole derivatives Chemical class 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses dihydroqinghaosus shown in Formulas I to prepare the application in anti-angiogenic medicaments, has widened the pharmaceutical applications of dihydroqinghaosu.
Description
Technical field
The invention belongs to the medical usage technical fields of compound, are related to a kind of dihydroqinghaosu and are preparing anti-blood
The application in drug that pipe generates.
Background technique
Qinghaosu and its derivative have efficient, quick and less toxic antimalarial active, obtain in worldwide extensively
Using.Recent study, which shows qinghaosu and its derivative also, to be had anti-inflammatory, antibacterium pyemia, anti-tissue fibrosis and resists
The multiple biological activities such as tumour.At present to the research of qinghaosu be concentrated mainly on raising activity, widen drug effect, increase stability and
Dissolubility etc..Some active small moleculars or drug are introduced into dihydro in past research by seminar where inventor
In qinghaosu structure, the dihydroqinghaosu of various structures type is devised, by the exploration of condition, simple, high yield
Ground realizes the synthesis of these target compounds, although and find that part of compound itself does not have antibacterial action, its
It can be used as the Trimethoprim of beta-lactam antibiotic.
Angiogenesis, including solid tumor, intraocular neovascularization syndrome are all referred in the pathogenesis of a variety of diseases
Such as proliferative retinopathy and age-related macular degeneration.Compared with normal histocyte, in entity tumor, newly
The generation of blood vessel can make tumour cell obtain growth vigor and autonomous proliferation ability.Meanwhile research find it is micro- in tumor biopsy
Exist between vessel density and survival and centainly contacts.Vascular endothelial growth factor (VEGF) normal angiogenesis with
And important adjustment effect is played in tumour and the relevant abnormal vascular generation of ophthalmology disease.Inhibition to VEGF signal path
The generation and development of the progress and other complication with the characteristics of abnormal angiogenesis of kinds of tumors can be limited.
Summary of the invention
It is an object of the invention to investigate activity of the dihydroqinghaosu in terms of anti-angiogenesis, to widen dihydro
The pharmaceutical applications of artemisinin derivative.
Through studying, the invention provides the following technical scheme:
1. dihydroqinghaosu shown in Formulas I or its raceme, stereoisomer, tautomer, nitrogen oxides,
Pharmaceutically acceptable salt is preparing the application in anti-angiogenic medicaments:
In Formulas I, n is 1 or 2；
Y is-NR1R2、
R1And R2It independently is H, C1-C3 alkyl or C1-C3 hydroxyalkyl；
R3For H, C1-C3 alkyl, C1-C3 hydroxyalkyl, phenyl substituted or unsubstituted, tertbutyloxycarbonyl, benzyloxycarbonyl group or rouge
Fat acyl group；Substituent group on the phenyl is one or more, is independently selected from halogen, hydroxyl, amino or C1-C3 alkyl；
R4And R5It independently is H or C1-C3 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C3 alkyl；
R8For H, C1-C3 alkyl, C1-C3 alkylthio group, phenyl substituted or unsubstituted；Substituent group on the phenyl is one
Or it is multiple, it is independently selected from halogen, hydroxyl, amino or C1-C3 alkyl.
Further, in Formulas I,
R1And R2It independently is H, C1-C2 alkyl or C1-C2 hydroxyalkyl；
R3For H, C1-C2 alkyl, C1-C2 hydroxyalkyl, phenyl substituted or unsubstituted, tertbutyloxycarbonyl, benzyloxycarbonyl group or alkane
Acyl group；Substituent group on the phenyl is one or more, is independently selected from halogen, hydroxyl, amino or C1-C2 alkyl；
R4And R5It independently is H or C1-C2 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C2 alkyl；
R8For H, C1-C2 alkyl, C1-C2 alkylthio group, phenyl substituted or unsubstituted；Substituent group on the phenyl is one
Or it is multiple, it is independently selected from halogen, hydroxyl, amino or C1-C2 alkyl.
Further, in Formulas I,
R1And R2It independently is H, C1-C2 alkyl or C1-C2 hydroxyalkyl；
R3For H, C1-C2 alkyl, C1-C2 hydroxyalkyl, phenyl, tertbutyloxycarbonyl, benzyloxycarbonyl group or acetyl group；
R4And R5It independently is H or C1-C2 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C2 alkyl；
R8For H, C1-C2 alkyl, C1-C2 alkylthio group or phenyl.
Further, in Formulas I,
R1And R2It independently is H, methyl, ethyl or ethoxy；
R3For H, methyl, ethoxy, phenyl or tertbutyloxycarbonyl；
R4And R5It independently is H or methyl；
R6And R7It independently is H or amino；
R8For H, methyl, methyl mercapto or phenyl.
Further, dihydroqinghaosu shown in Formulas I is any one of following compound:
Further, dihydroqinghaosu shown in Formulas I is any one of following compound: 1c, 2a-4,2a-5,
2b-1,4b-6,4b-8,5b-6。
Unless otherwise stated, the term " raceme " in the present invention refers to that the optics being made of equal parts of enantiomers is not active
Organic matter." stereoisomer " refers to atom composition and molecule bonded identical and that atom is different on three-dimensional arrangement." mutually
Tautomeric " refers to the functional isomer because atom a certain in molecule generates due to two positions are moved rapidly." nitrogen oxidation
Object " refers to that three-level nitrogen connection oxygen atom is formed+N-O-The organic matter of structural unit." pharmaceutically acceptable salt " can be acidity
Salt is also possible to basic salt, such as inorganic acid salt, acylate, inorganic base salts or organic alkali salt.
The beneficial effects of the present invention are: the invention discloses dihydroqinghaosus shown in Formulas I to prepare anti-blood
The application in drug that pipe generates, has widened the pharmaceutical applications of dihydroqinghaosu.
Specific embodiment
It, below will be to preferred reality of the invention in order to keep the purpose of the present invention, technical scheme and beneficial effects clearer
Example is applied to be described in detail.
Main agents and specification used in preferred embodiment: dimethylamine, diethylamine, ethanol amine, n-formyl sarcolysine ethylethanolamine, two
Ethanol amine, pyrrolidines, piperidines, morpholine, acetonitrile, methylene chloride (Chongqing chemical reagent head factory, AR)；Piperazine anhydrous, N- methyl piperazine
The bromo- 1- propyl alcohol of piperazine, N- hydroxyethyl piperazine, N-Boc- piperazine, N- phenylpiperazine, 3-, imidazoles, 2-methylimidazole, 4-methylimidazole,
Pyrazoles, 3,5- dimethyl pyrazole, benzimidazole, 1,2,3- triazole, 1,2,4- triazole, benzotriazole, amino -1,2 3-,
4- triazole, 3- amino -5- sulfydryl -1,2,4- triazole, 1-H- tetrazole, 5- methyl tetrazole, 5- phenyl tetrazole, 5- first
Mercapto tetrazole (Shanghai Da Rui Fine Chemical Co., Ltd, > 98%)；1- hydroxyl-benzotriazole (the covalent subject in Shanghai
Skill company, technical grade)；Dihydroartemisinine (Wuling Shan Mountain pharmaceutical Co. Ltd, Chongqing Holley, AR)；(Shanghai reaches auspicious fine bromoethanol
Chemical Co., Ltd., AR)；46.5%BF3.Et2O (Shanghai crystalline substance pure reagent Co., Ltd, AR)；Remaining reagent is commercially available chemistry
Pure or analysis net product, not purified direct use.
Key instrument and model used in preferred embodiment: accurate micro melting point apparatus (X-6, the triumphant instrument of Beijing good fortune
Co., Ltd)；Digital automatic polarimeter (WZZ-2S, Shanghai Precision Scientific Apparatus Co., Ltd)；Superconduction NMR spectrum
Instrument (AV-300, Bruker, Switzerland)；High-resolution mass spectrometer (HR ESI MS) (Varian7.0T, Varian, USA).
The synthesis of embodiment 1, DHA amine derivant
1, the synthesis of DHA fatty amines derivative 1
DHA fatty amines derivative 1a-1h is according to document (Chong Wu, et al.Design, Synthesis and
Evaluation of the Antibacterial Enhancement Activities of Amino
Dihydroartemisinin Derivatives.Molecules, 2013,18,6866-6882) described in compound 4a-4u
Preparation method prepared.
2, the synthesis of DHA piperazine derivative 2
1) synthesis of intermediate M1
Intermediate M1 according to Chinese patent 104418864B (conjugate of dihydroartemisinine and carbostyril compound and its
Preparation method and application) described in the preparation method of intermediate compound I M1 and IM2 prepare.
2) synthesis of DHA piperazine derivative 2a-1~2a-5 and 2b-1~2b-5
M1, CH are sequentially added in 100mL round-bottomed flask3CN、K2CO3And piperazine or substituted-piperazinyl, temperature control stirring react,
TLC monitors reaction process.After reaction, CH is added2Cl215mL and saturation NaCl aqueous solution 20mL, stratification, water layer are used
CH2Cl2(10mL × 2) extraction merges organic phase, saturated salt solution 20mL washing, anhydrous Na2SO4Dry, vacuum rotary steam removes
CH2Cl2Crude product or sterling are obtained, column chromatographs when necessary, and it is dry, up to target compound 2.Specific synthesis condition and it the results are shown in Table 1.
The synthesis condition and result of 1 target compound 2 of table
2 characterize data of target compound is as follows:
2a-1:1H NMR(300MHz,CDCl3) δ: 0.90 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=
6.6Hz, H-14), 1.43 (3H, s, H-15), 1.22-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.37-2.60 (12H,
M, H-1, H-11, H-17~H-19), 3.52-3.59 (1H, m, H-16), 3.91-3.98 (1H, m, H-16), 4.80 (1H, s, H-
12),5.45(1H,s,H-5).
2a-2:1H NMR(300MHz,CDCl3) δ: 0.90 (3H, d, J=7.5Hz, H-13), 0.96 (3H, d, J=
6.6Hz, H-14), 1.43 (3H, s, H-15), 1.46 (9H, s, H-22), 1.22-2.06 (10H, m, H-2, H-3, H-7~H-
10), 2.30 (3H, s, H-20), 2.37-2.60 (12H, m, H-1, H-11, H-17~H-19), 3.52-3.59 (1H, m, H-
16),3.91-3.98(1H,m,H-16),4.80(1H,s,H-12),5.45(1H,s,H-5).
2a-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.89 (3H, d, J=7.3Hz, H-13), 0.95 (3H, d, J=6.0Hz, H-14), 1.42 (3H, s, H-15), 1.15-2.06
(10H, m, H-2, H-3, H-7~H-10), 2.28-2.59 (14H, m, H-1, H-11, H-17~H-20), 3.36-4.43 (1H,
M, H-16), 3.62 (2H, t, J=5.3Hz, H-21), 3.84-3.91 (1H, m, H-16), 4.77 (1H, d, J=3.3Hz, H-
12),5.30(1H,s,H-22),5.38(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:103.98(C-4),101.90(C-
12),87.84(C-5),81.07(C-6),68.54(C-16),59.36(C-22),57.72(C-20),55.52(C-17),
53.26(C-19),52.45(C-1),46.76(C-18),44.31(C-7),37.39(C-11),36.32(C-10),34.57
(C-3),30.76(C-9),26.12(C-8),24.63(C-15),24.30(C-2),20.29(C-14),13.01(C-13).HR
MS:C23H40N2O6[M+H]+Calculated value 441.2959, measured value 441.2954.
2a-4:m.p.:107.8-109.1℃； 1H NMR(300MHz,
CDCl3) δ: 0.90 (3H, d, J=7.2Hz, H-13), 0.96 (3H, d, J=6.0Hz, H-14), 1.43 (3H, s, H-15),
1.46 (9H, s, H-22), 1.22-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.65 (8H, m, H-1, H-11, H-
17 and H-18),3.40-3.44(4H,m,H-19),3.52-3.58(1H,m,H-16),3.92-4.00(1H,m,H-16),
4.80(1H,s,H-12),5.46(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:154.6(C-21),104.0(C-4),
101.9(C-12),87.8(C-5),81.0(C-6),79.7(C-22),66.0(C-16),57.9(C-17),53.5(C-19),
52.0(C-1),49.2(C-18),44.4(C-7),37.4(C-11),36.4(C-10),34.6(C-3),30.8(C-9),28.4
(C-23),26.4(C-17),26.1(C-8),24.6(C-15),24.4(C-2),20.4(C-14),13.0(C-13).HR MS:
C27H40N2O5[M+H]+Calculated value 497.3221, measured value 497.3222.
2a-5:m.p.:90.0-91.7℃； 1H NMR(300MHz,
CDCl3) δ: 0.90 (3H, d, J=7.2Hz, H-13), 0.95 (3H, d, J=6.0Hz, H-14), 1.44 (3H, s, H-15),
1.23-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.42 (1H, m, H-1), 2.59-2.70 (7H, m, H-11, H-
17 and H-18), 3.21 (4H, t, J=7.5Hz, H-19), 3.58-3.65 (1H, m, H-16), 3.98-4.05 (1H, m, H-
16), 4.83 (1H, d, J=2.7Hz, H-12), 5.48 (1H, s, H-5), 6.89 (1H, t, J=7.2Hz, H-23), 6.94 (2H,
D, J=7.8Hz, H-21), 7.25-7.30 (2H, m, H-22)；13C NMR(75MHz,CDCl3)δ:151.3(C-20),129.1
(C-22),120.0(C-23),116.0(C-21),104.0(C-4),102.0(C-12),87.9(C-5),81.1(C-6),
66.0(C-16),57.9(C-17),53.5(C-19),52.6(C-1),49.2(C-18),44.4(C-7),37.5(C-11),
36.4(C-10),34.7(C-3),30.9(C-9),26.2(C-8),24.7(C-15),24.4(C-2),20.3(C-14),13.1
(C-13).HR MS:C27H40N2O5(M+H)+Calculated value 473.3010, measured value 473.3014.
2b-1: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.89 (3H, d, J=7.2Hz, H-13), 0.96 (3H, d, J=6.0Hz, H-14), 1.44 (3H, s, H-15), 1.26-2.06
(12H, m, H-2, H-3, H-7~H-10 and H-17), 2.37-2.62 (12H, m, H-1, H-11, H-18~H-20), 3.37-
3.44(1H,m,H-16),3.84-3.92(1H,m,H-16),4.77(1H,s,H-12),5.39(1H,s,H-5).
2b-2: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.89 (3H, d, J=7.2Hz, H-13), 0.96 (3H, d, J=6.0Hz, H-14), 1.44 (3H, s, H-15), 1.26-2.06
(12H, m, H-2, H-3, H-7~H-10 and H-17), 2.30 (3H, s, H-20), 2.37-2.62 (12H, m, H-1, H-11,
H-18~H-20), 3.37-3.44 (1H, m, H-16), 3.84-3.92 (1H, m, H-16), 4.77 (1H, s, H-12), 5.39
(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:104.1(C-4),101.9(C-12),87.8(C-5),81.0(C-6),
66.5(C-16),55.5(C-18),55.0(C-19),53.1(C-20),52.5(C-21),46.0(C-1),44.4(C-7),
37.1(C-11),36.4(C-10),34.6(C-3),30.9(C-9),27.0(C-17),26.2(C-8),24.6(C-15),
24.4(C-2),20.3(C-14),13.0(C-13).HR MS:C23H40N2O5[M+H]+Calculated value 425.3010, measured value
425.3010.
2b-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.89 (3H, d, J=7.3Hz, H-13), 0.95 (3H, d, J=6.0Hz, H-14), 1.42 (3H, s, H-15), 1.15-2.06
(12H, m, H-2, H-3, H-7~H-10 and H-17), 2.28-2.59 (14H, m, H-1, H-11, H-17~H-20), 3.36-
3.43 (1H, m, H-16), 3.62 (2H, t, J=5.3Hz, H-21), 3.84-3.91 (1H, m, H-16), 4.77 (1H, d, J=
3.3Hz,H-12),5.30(1H,s,H-23),5.38(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:104.00(C-4),
101.90(C-12),87.81(C-5),81.04(C-6),66.43(C-16),59.31(C-22),57.68(C-20),55.42
(C-17),53.06(C-19),52.76(C-18),52.49(C-1),44.35(C-7),37.42(C-11),36.35(C-10),
34.56(C-3),30.84(C-9),26.97(C-17),26.12(C-8),24.61(C-15),24.40(C-2),20.30(C-
14),12.97(C-13).HR MS:C24H42N2O6[M+H]+Calculated value 455.3116, measured value 455.3115.
2b-4: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.90 (3H, d, J=7.5Hz, H-13), 0.96 (3H, d, J=6.0Hz, H-14), 1.43 (3H, s, H-15), 1.47 (9H, s,
), H-23 1.26-2.06 (12H, m, H-2, H-3, H-7~H-10 and H-17), 2.32-2.43 (1H, m, H-1), 2.61-
2.64 (1H, m, H-11), 3.40-3.46 (11H, m, H-16, H-18~H-20), 3.92-4.00 (1H, m, H-16), 4.19
(2H, t, J=6.3Hz, H-14), 4.76 (1H, s, H-12), 5.37 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:
154.6(C-21),104.0(C-4),101.9(C-12),87.8(C-5),81.0(C-6),79.7(C-22),66.5(C-16),
55.3(C-18),52.6(C-20),52.5(C-19),52.0(C-1),44.4(C-7),37.4(C-11),36.4(C-10),
34.6(C-3),30.8(C-9),28.4(C-23),26.4(C-17),26.1(C-8),24.6(C-15),24.4(C-2),20.4
(C-14),13.0(C-13).HR MS:C27H46N2O7[M+H]+Calculated value 511.3378, measured value 511.3370.
2b-5:1H NMR(300MHz,CDCl3) δ: 0.92 (3H, d, J=7.5Hz, H-13), 0.96 (3H, d, J=
5.7Hz, H-14), 1.44 (3H, s, H-15), 1.23-2.06 (12H, m, H-2, H-3, H-7~H-10 and H-17), 2.32-
2.42(1H,m,H-1),2.49-2.65(7H,m,H-11,H-18 and H-19),3.22-3.25(4H,m,H-20),3.40-
3.48 (1H, m, H-16), 3.88-3.96 (1H, m, H-16), 4.80 (1H, d, J=2.4Hz, H-12), 5.41 (1H, s, H-5),
6.87 (1H, t, J=7.2Hz, H-23), 6.94 (2H, d, J=7.8Hz, H-21), 7.25-7.30 (2H, m, H-22)；13C NMR
(75MHz,CDCl3)δ:151.2(C-21),129.1(C-23),119.7(C-24),116.0(C-22),104.0(C-4),
102.0(C-12),87.9(C-5),81.1(C-6),66.5(C-16),55.6(C-18),53.2(C-20),52.6(C-1),
49.1(C-19),44.4(C-7),37.5(C-11),36.4(C-10),34.6(C-3),30.9(C-9),28.4(C-17),
26.2(C-8),24.7(C-15),24.5(C-2),20.4(C-14),13.0(C-13).HR MS:C28H42N2O5[M+H]+It calculates
Value 487.3167, measured value 487.3162.
The synthesis of embodiment 2, DHA azole derivative
Sequentially added in 100mL round-bottomed flask azole compounds YH, N,N-dimethylformamide (DMF) and alkali (NaH or
K2CO3), after stirring 15min, M1, temperature control stirring reaction is added, TLC monitors reaction process.After the reaction was completed, ethyl acetate is added
(EtOAc) 15mL and saturation NaCl aqueous solution 20mL, stratification, water layer are extracted with EtOAc (10mL × 2), merge organic phase,
Saturated salt solution 20mL washing, anhydrous Na2SO4Dry, vacuum rotary steam removes EtOAc and obtains crude product or sterling, and column chromatographs when necessary,
It is dry, up to target compound 3,4,5.Specific synthesis condition and it the results are shown in Table 2,3,4.
The synthesis condition and result of 2 target compound 3 of table
The synthesis condition and result of 3 target compound 4 of table
The synthesis condition and result of 4 target compound 5 of table
The characterize data of target compound 3-5 is as follows:
3a-1:m.p.:93.7-95.1℃； 1H NMR(300MHz,
CDCl3) δ: 0.80 (3H, d, J=7.4Hz, H-14), 0.93 (3H, d, J=5.5Hz, H-13), 1.42 (3H, s, H-15),
1.17-2.08 (10H, m, H-2, H-3, H-7~H-10), 2.34 (1H, td, J=14.0,3.9Hz, H-1), 2.51-2.65
(1H, m, H-11), 3.68-3.81 (1H, m, H-16), 4.19-4.41 (3H, m, H-16 and H-17), 4.75 (1H, d, J=
3.4Hz,H-12),5.13(1H,s,H-5),6.23(s,1H,H-19),7.42(1H,s,H-20),7.51(1H,s,H-20)；13C
NMR(75MHz,CDCl3)δ:139.29(C-20),129.67(C-19),105.16(C-18),103.98(C-4),101.87
(C-12),87.70(C-5),80.89(C-6),66.66(C-16),52.37(C-1),51.99(C-17),44.10(C-7),
37.11(C-11),36.29(C-10),34.46(C-3),30.62(C-9),26.08(C-8),24.57(C-15),24.14(C-
2),20.29(C-14),12.81(C-13).HR MS:C20H30N2O5(M+Na)+Calculated value 401.2047, measured value
401.2050.
3a-2: yellow oil； 1H NMR(300MHz,CDCl3)δ:0.85
(3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=6.1Hz, H-13), 1.44 (3H, s, H-15), 1.22-2.07 (10H,
M, H-2, H-3, H-7~H-10), 2.32-2.38 (1H, m, H-1), 2.61-2.63 (1H, m, H-11), 3.62-3.68 (1H, m,
H-16),4.15-4.21(3H,m,H-16 and H-17),4.76(1H,s,H-12),5.11(1H,s,H-5),7.00(1H,s,
H-19),7.09(1H,s,H-18),7.62(1H,s,H-20)；13C NMR(75MHz,CDCl3)δ:128.7(C-20),123.1
(C-19),118.9(C-18),104.1(C-4),102.0(C-12),87.8(C-5),80.8(C-6),67.0(C-16),52.3
(C-1),47.2(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-
8),24.6(C-15),24.3(C-2),20.3(C-14),13.0(C-13).HR MS:C20H30N2O5(M+H)+Calculated value
379.2228 measured value 379.2221.
3a-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.91 (3H, d, J=6.9Hz, H-14), 0.95 (3H, d, J=6.3Hz, H-13), 1.45 (3H, s, H-15), 1.19-2.06
(10H, m, H-2, H-3, H-7~H-10), 2.12 (3H, s, H-21), 2.32-2.43 (1H, m, H-1), 2.59-2.66 (1H, m,
), H-11 3.40-3.52 (4H, m, H-16 and H-17), 4.69 (1H, d, J=2.7Hz, H-12), 5.39 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:127.8(C-18),127.2(C-20),118.8(C-19),104.2(C-4),102.0(C-
12),87.8(C-5),80.9(C-6),66.9(C-16),52.4(C-1),47.8(C-17),44.0(C-7),37.2(C-11),
36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0
(C-13),12.7(C-21).HR MS:C21H32N2O5(M+H)+Calculated value 393.2384, measured value 393.2382.
3a-4: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.85 (3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=4.8Hz, H-13), 1.43 (3H, s, H-15), 1.22-2.07
(10H, m, H-2, H-3, H-7~H-10), 2.29-2.34 (1H, m, H-1), 2.41 (3H, s, H-21), 2.61-2.63 (1H, m,
), H-11 3.58-3.63 (1H, m, H-16), 3.99-4.16 (3H, m, H-16 and H-17), 4.76 (1H, d, J=3.3Hz,
H-12),5.08(1H,s,H-5).6.88(1H,s,H-19),6.92(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:
126.7(C-20 and C-19),118.9(C-18),104.2(C-4),102.0(C-12),87.8(C-5),80.9(C-6),
66.8(C-16),52.4(C-1),45.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),34.4(C-3),
30.6(C-9),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0(C-13),12.9(C-21).HR
MS:C21H32N2O5(M+H)+Calculated value 393.2384, measured value 393.2386.
3a-5: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.81 (3H, d, J=7.2Hz, H-14), 0.87 (3H, d, J=6.3Hz, H-13), 1.42 (3H, s, H-15), 1.26-2.08
(10H, m, H-2, H-3, H-7~H-10), 2.29-2.37 (1H, m, H-1), 2.21 (3H, s, H-21), 2.28 (3H, s, H-
22),2.51-2.59(1H,m,H-11),3.64-3.69(1H,m,H-16),4.12-4.28(3H,m,H-16 and H-17),
4.75 (1H, d, J=2.7Hz, H-12), 5.07 (1H, s, H-5) .5.86 (1H, s, H-19)；13C NMR(75MHz,CDCl3)δ:
147.4(C-20),139.4(C-19),104.6(C-4),103.9(C-19),101.7(C-12),87.6(C-5),80.9(C-
6),66.4(C-16),52.3(C-1),47.9(C-17),44.2(C-7),37.0(C-11),36.3(C-10),34.6(C-3),
30.7(C-9),26.1(C-8),24.5(C-15),24.0(C-2),20.2(C-14),13.0(C-13),12.8(C-21),
11.1(C-22)；HR MS:C22H34N2O5(M+Na)+Calculated value 429.2360, measured value 429.2356.
3a-6: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.76 (3H, d, J=7.5Hz, H-14), 0.83 (3H, d, J=6.0Hz, H-13), 1.39 (3H, s, H-15), 1.15-1.99
(10H, m, H-2, H-3, H-7~H-10), 2.24-2.35 (H, m, H-1), 2.52-2.59 (H, m, H-11), 3.70-3.76
(1H, m, H-16), 4.28-4.43 (3H, m, H-16 and H-17), 4.73 (1H, d, J=2.7Hz, H-12), 4.91 (1H, s,
), H-5 7.30 (2H, t, J=2.4Hz, H-21 and H-22), 7.42 (1H, d, J=7.5Hz, H-23), 7.80 (1H, d, J=
7.5Hz,H-20),7.95(1H,s,H-18).
3b-1:m.p.:109.3-110.2℃； 1H NMR(300MHz,
CDCl3) δ: 0.94 (3H, d, J=6.9Hz, H-14), 0.96 (3H, d, J=5.6Hz, H-13), 1.44 (3H, s, H-15),
1.17-2.22 (12H, m, H-2, H-3, H-7~H-10 and H-17), 2.37 (1H, m, H-1), 2.59-2.72 (1H, m, H-
11), 3.28-3.36 (1H, m, H-16), 3.82-3.89 (1H, m, H-16), 4.23 (2H, t, J=7.0Hz, H-18), 4.78
(1H, d, J=3.3Hz, H-12), 5.40 (1H, s, H-5), 6.25 (1H, s, H-20), 7.37 (1H, s, H-19), 7.52 (1H,
s,H-21)；13C NMR(75MHz,CDCl3)δ:139.31(C-21),129.09(C-20),105.25(C-19),104.06(C-
4),102.01(C-12),87.84(C-5),81.00(C-6),64.96(C-16),52.47(C-1),49.00,44.29(C-
7),37.38(C-11),36.33(C-10),34.54(C-3),30.82(C-17),30.49(C-9),26.13(C-8),24.62
(C-15),24.46(C-2),20.33(C-14),13.09(C-13).HR MS:C21H32N2O5(M+Na)+Calculated value
415.2203 measured value 415.2202.
3b-2: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.94-0.98 (6H, m, H-13 and H-14), 1.43 (3H, s, H-15), 1.25-2.06 (12H, m, H-2, H-3, H-7~H-
10 and H-17),2.33-2.42(1H,m,H-1),2.60-2.71(1H,m,H-11),3.33-3.40(1H,m,H-16),
3.83-3.90 (1H, m, H-16), 4.04 (2H, t, J=7.2Hz, H-18), 4.78 (1H, s, H-12), 5.37 (1H, s, H-5),
6.91(1H,s,H-20),7.07(1H,s,H-19),7.47(1H,s,H-21)；13C NMR(75MHz,CDCl3)δ:137.1
(21),129.5(C-20),118.8(C-19),104.1(C-4),102.0(C-12),87.9(C-5),80.9(C-6),64.4
(C-16),52.5(C-1),44.2(C-7),43.8(C-18),37.5(C-11),36.3(C-10),34.5(C-3),31.2(C-
17),30.8(C-9),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.1(C-13).HR MS:
C21H32N2O5[M+H]+Calculated value 393.2384, measured value 393.2386.
3b-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:0.91
(3H, d, J=6.9Hz, H-14), 0.95 (3H, d, J=6.3Hz, H-13), 1.45 (3H, s, H-15), 1.19-2.06 (12H,
M, H-2, H-3, H-7~H-10 and H-17), 2.13 (3H, s, H-22), 2.32-2.43 (1H, m, H-1), 2.59-2.66
(1H, m, H-11), 3.40-3.52 (4H, m, H-16 and H-18), 4.69 (1H, d, J=2.7Hz, H-12), 5.39 (1H, s,
H-5)；13C NMR(75MHz,CDCl3)δ:127.9(C-19),127.2(C-21),118.9(C-20),104.2(C-4),
102.0(C-12),87.8(C-5),80.9(C-6),66.9(C-16),52.4(C-1),47.8(C-18),44.0(C-7),
37.2(C-11),36.3(C-10),34.4(C-3),30.6(C-9),29.7(C-17),26.1(C-8),24.6(C-15),
24.2(C-2),20.3(C-14),13.0(C-13),12.7(C-21).HR MS:C22H34N2O5[M+H]+Calculated value
407.2540 measured value 407.2542.
3b-4: yellow oil； 1H NMR(300MHz,CDCl3)δ:0.85
(3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=4.8Hz, H-13), 1.43 (3H, s, H-15), 1.22-2.07 (12H,
M, H-2, H-3, H-7~H-10 and H-17), 2.29-2.34 (1H, m, H-1), 2.41 (3H, s, H-21), 2.61-2.63
(1H, m, H-11), 3.58-3.63 (1H, m, H-16), 3.99-4.16 (3H, m, H-16 and H-17), 4.76 (1H, d, J=
3.3Hz,H-12),5.08(1H,s,H-5).6.88(1H,s,H-20),6.92(1H,s,H-19)；13C NMR(75MHz,
CDCl3)δ:126.7(C-20 and C-19),118.9(C-18),104.2(C-4),102.0(C-12),87.8(C-5),
80.9(C-6),66.8(C-16),52.4(C-1),45.8(C-17),44.0(C-7),37.2(C-11),36.3(C-10),
34.4(C-3),30.6(C-9),29.6(C-17),26.1(C-8),24.6(C-15),24.2(C-2),20.3(C-14),13.0
(C-13),12.9(C-21).HR MS:C22H34N2O5[M+H]+Calculated value 407.2540, measured value 407.2537.
3b-5: yellow oil； 1H NMR(400MHz,CDCl3)δ:0.93
(3H, d, J=7.4Hz, H-13), 0.96 (3H, d, J=7.4Hz, H-14), 1.44 (3H, s, H-15), 1.37-2.12 (12H,
M, H-2, H-3, H-7~H-10 and H-17), 2.21 (3H, s, H-21), 2.29 (3H, s, H-22), 2.39 (1H, m, H-1),
2.61-2.68 (1H, m, H-11), 3.36-3.41 (1H, m, H-16), 3.85-3.90 (1H, m, H-16), 4.03 (2H, t, J=
7.1Hz, H-18), 4.80 (1H, d, J=2.4Hz, H-12), 5.45 (1H, s, H-5), 5.77 (1H, s, H-19)；13C NMR
(75MHz,CDCl3)δ:147.18(C-21 and C-23),138.39(C-20),104.77(C-4),103.98(C-20),
101.79(C-12),87.81(C-5),80.97(C-6),65.07(C-16),52.44(C-1),45.56(C-17),44.30
(C-7),37.30(C-11),36.31(C-10),34.54(C-3),30.79(C-9),30.53(C-18),26.07(C-8),
24.59(C-15),24.43(C-2),20.27(C-14),13.39(C-13),13.02(C-13),10.85(C-22 and C-
23).HR MS:C23H36N2O5[M+Na]+Calculated value 443.2516, measured value 443.2518.
3b-6: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.87 (3H, d, J=6.9Hz, H-13), 0.98 (3H, d, J=7.5Hz, H-14), 1.44 (3H, s, H-15), 1.26-2.16
(12H, m, H-2, H-3, H-7~H-10 and H-17), 2.33-2.43 (1H, m, H-1), 2.68-2.71 (1H, m, H-11),
3.39-3.47 (1H, m, H-16), 3.88-3.95 (1H, m, H-16), 4.30 (2H, t, J=7.2Hz, H-18), 4.82 (1H, d,
J=2.4Hz, H-12), 5.40 (1H, s, H-5), 7.30-7.33 (2H, m, H-22 and H-23), 7.41 (1H, d, J=
4.8Hz,H-21),7.82-7.85(1H,m,H-24),7.98(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:129.1
(C-21 and C-24),116.1(C-22 and C-23),104.0(C-4),102.0(C-12),87.8(C-5),81.0(C-
6),66.4(C-16),52.5(C-1),49.0(C-18),44.0(C-7),37.5(C-11),36.4(C-10),34.6(C-3),
30.7(C-9),29.7(C-17),26.2(C-8),24.7(C-15),24.5(C-2),20.4(C-14),13.0(C-13).HR
MS:C25H34N2O5[M+H]+Calculated value 443.2541, measured value 443.2538.
4a-1:m.p.:100.8-102.4℃； 1H NMR(300MHz,
CDCl3) δ: 0.74 (3H, d, J=7.2Hz, H-14), 0.93 (3H, d, J=5.4Hz, H-13), 1.42 (3H, s, H-15),
1.12-2.11 (10H, m, H-2, H-3, H-7~H-10), 2.34 (1H, m, H-1), 2.47-2.63 (1H, m, H-11), 3.89-
3.96(1H,m,H-16),4.33-4.40(1H,m,H-16),4.64(2H,m,H-17),4.77(1H,s,H-12),5.21(1H,
s,H-5),7.60(2H,s,H-18)；13C NMR(75MHz,CDCl3)δ:133.96(C-18),103.97(C-4),102.10
(C-12),87.79(C-5),80.92(C-6),66.12(C-16),54.73(C-17),52.37(C-1),44.12(C-7),
37.13(C-11),36.29(C-10),34.47(C-3),30.58(C-9),26.08(C-8),24.58(C-15),23.93(C-
2),20.31(C-14),12.67(C-13).HR MS:C19H29N3O5[M+Na]+Calculated value 402.1999, measured value
402.1997.
4a-2:m.p.:128.4-129.7℃； 1H NMR(300MHz,
CDCl3) δ: 0.81 (3H, d, J=7.2Hz, H-14), 0.95 (3H, d, J=5.4Hz, H-13), 1.42 (3H, s, H-15),
1.16-2.08 (10H, m, H-2, H-3, H-7~H-10), 2.35 (1H, m, H-1), 2.56-2.65 (1H, m, H-11), 3.77-
3.84(1H,m,H-16),4.26-4.33(1H,m,H-16),4.52-4.60(1H,m,H-17),4.63-4.72(1H,m,H-
17), 4.78 (1H, d, J=3.2Hz, H-12), 5.16 (1H, s, H-5), 7.62 (1H, s, H-18), 7.72 (1H, s, H-19)；13C NMR(75MHz,CDCl3)δ:133.62(C-19),123.94(C-18),104.11(C-4),102.06(C-12),87.77
(C-5),80.78(C-6),66.46(C-16),52.33(C-1),50.12(C-17),43.97(C-7),37.18(C-11),
36.23(C-10),34.35(C-3),30.54(C-9),26.04(C-8),24.51(C-15),24.19(C-2),20.30(C-
14),12.80(C-13).HR MS:C19H29N3O5[M+Na]+Calculated value 402.1999, measured value 402.1993.
4a-3:m.p.:93.5-95.2℃； 1H NMR(300MHz,
CDCl3) δ: 0.78 (3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=4.5Hz, H-13), 1.42 (3H, s, H-15),
1.19-2.08 (10H, m, H-2, H-3, H-7~H-10), 2.31-2.39 (1H, m, H-1), 2.58-2.62 (1H, m, H-11),
3.74-3.81(1H,m,H-16),4.09-4.17(1H,m,H-16),4.36-4.38(2H,m,H-17),4.78(1H,s,H-
12),5.17(1H,s,H-5),7.96(1H,s,H-19),8.12(1H,s,H-18).
4a-4:m.p.:100.5~104.3 DEG C； 1H NMR(300MHz,
CDCl3) δ: 0.89 (3H, d, J=7.4Hz, H-14), 0.96 (3H, d, J=5.6Hz, H-13), 1.44 (3H, s, H-15),
1.27-2.10 (10H, m, H-2, H-3, H-7~H-10), 2.37 (1H, td, J=14.2,3.7Hz, H-1), 2.63-2.74
(1H, m, H-11), 3.61-3.70 (1H, m, H-16), 4.08-4.23 (3H, m, H-16 and H-17), 4.81 (1H, d, J=
3.5Hz,H-12),5.27(1H,s,H-5),7.80(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:154.04,
140.14,104.17,102.24,87.74,80.72,66.47,52.25,43.91,43.51,37.23,36.18,34.25,
30.49,25.95,24.47,24.40,20.21,12.83.HR MS:C19H30N4O5[M+Na]+Calculated value 417.2108, measurement
Value 417.2105.
4a-5:m.p.:97.3-98.5℃； 1H NMR(300MHz,
CDCl3) δ: 0.91 (3H, d, J=7.4Hz, H-14), 0.94 (3H, d, J=6.3Hz, H-13), 1.41 (3H, s, H-15),
1.21-2.09 (10H, m, H-2, H-3, H-7~H-10), 2.37 (1H, td, J=14.1,3.6Hz, H-1), 2.54-2.69
(1H, m, H-11), 3.23 (2H, t, J=5.8Hz, H-17), 3.82-3.66 (1H, m, H-16), 3.98-4.06 (1H, m, H-
16), 4.83 (1H, d, J=3.2Hz, H-12), 5.06 (2H, s, H-20), 5.57 (1H, s, H-5)；13C NMR(75MHz,
CDCl3)δ:163.32,148.19,104.35,101.96,88.16,81.26,67.28,52.40,44.26,37.28,
36.30,34.52,32.05,30.87,25.94,24.52,24.33,20.33,12.93.HR MS:C19H30N4O5S[M-H]-Meter
Calculation value 425.1864, measured value 425.1866.
4a-6:m.p.:139.3-140.5℃； 1H NMR(300MHz,
CDCl3) δ: 0.63 (3H, d, J=7.5Hz, H-13), 0.85 (3H, d, J=6.0Hz, H-14), 1.39 (3H, s, H-15),
0.97-1.99 (10H, m, H-2, H-3, H-7~H-10), 2.23-2.34 (1H, m, H-1), 2.47-2.50 (1H, m, H-11),
3.88-3.93 (1H, m, H-16), 4.45-4.52 (1H, m, H-16), 4.73 (1H, d, J=3.0Hz, H-12), 4.80-4.93
(3H, m, H-5 and H-17), 7.37 (1H, t, J=7.5Hz, H-21), 7.49 (1H, t, J=7.2Hz, H-20), 7.57
(1H, d, J=8.1Hz, H-19), 7.86 (2H, d, J=8.4Hz, H-22)；13C NMR(75MHz,CDCl3)δ:145.8(C-
23),133.5(C-18),127.1(C-21),123.8(C-20),119.8(C-22),109.6(C-19),104.0(C-4),
102.0(C-12),87.6(C-5),80.7(C-6),66.1(C-16),52.2(C-1),48.0(C-17),43.9(C-7),
36.9(C-11),36.2(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.4(C-15),24.0(C-2),20.2
(C-14),12.6(C-13).HR MS:C23H31N3O5[M+Na]+Calculated value 452.2156, measured value 452.2151.
4a-7:m.p.:65.6-67.3℃； 1H NMR(300MHz,
CDCl3) δ: 0.73 (3H, d, J=6.9Hz, H-13), 0.87 (3H, d, J=7.5Hz, H-14), 1.42 (3H, s, H-15),
1.01-1.99 (10H, m, H-2, H-3, H-7~H-10), 2.25-2.33 (1H, m, H-1), 2.49-2.55 (1H, m, H-11),
4.00-4.04(1H,m,H-16),4.62-4.68(1H,m,H-16),4.81(1H,s,H-12),4.89-5.03(3H,m,H-5
And H-17), 7.38 (1H, d, J=9.0Hz, H-20), 7.86 (2H, d, J=9.3Hz, H-19)；13C NMR(75MHz,
CDCl3)δ:143.5(C-18),126.2(C-20),117.9(C-19),103.9(C-4),101.7(C-12),87.7(C-5),
80.8(C-6),65.5(C-16),56.5(C-17),52.2(C-1),44.0(C-7),36.7(C-11),36.3(C-10),
34.3(C-3),30.6(C-9),26.1(C-8),24.5(C-15),23.9(C-2),20.1(C-14),12.7(C-13).HR
MS:C23H31N3O5[M+Na]+Calculated value 452.2156, measured value 452.2159.
4a-8:m.p.:131.2-132.7℃； 1H NMR(300MHz,
CDCl3) δ: 0.91 (3H, d, J=7.2Hz, H-14), 0.95 (3H, d, J=6.0Hz, H-13), 1.44 (3H, s, H-15),
1.26-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.43 (H, m, H-1), 2.65-2.72 (H, m, H-11),
3.83~3.90 (1H, m, H-16), 4.22-4.29 (1H, m, H-16), 4.75 (2H, t, J=3.6Hz, H-17), 4.87 (1H,
S, H-12), 5.45 (1H, s, H-5), 7.40 (1H, t, J=7.5Hz, H-21), 7.52 (1H, t, J=7.5Hz, H-20), 7.62
(1H, d, J=8.4Hz, H-22), 8.03 (1H, d, J=8.4Hz, H-19)；13C NMR(75MHz,CDCl3)δ:143.5(C-
23),127.9(C-18),127.4(C-19),124.6(C-21),120.3(C-20),108.6(C-22),104.1(C-4),
102.3(C-12),88.0(C-5),81.0(C-6),79.7(C-17),65.5(C-16),52.5(C-1),44.3(C-7),
37.3(C-11),36.3(C-10),34.5(C-3),30.7(C-9),26.1(C-8),24.6(C-15),24.3(C-2),20.3
(C-14),12.9(C-13).HR MS:C23H31N3O6[M+Na]+Calculated value 468.2105, measured value 468.2098.
4b-1:m.p.:100.8-102.4℃； 1H NMR(300MHz,
CDCl3) δ: 0.94 (3H, d, J=7.2Hz, H-14), 0.96 (3H, d, J=6.2Hz, H-13), 1.43 (3H, s, H-15),
1.17-2.10 (10H, m, H-2, H-3, H-7~H-10), 2.16-2.28 (2H, m, H-17), 2.37 (1H, m, H-1), 2.56-
2.72(1H,m,H-11),3.26-3.43(1H,m,H-16),3.81-3.88(1H,m,H-16),4.54(2H,m,H-18),
4.79 (1H, d, J=3.2Hz, H-12), 5.44 (1H, s, H-5), 7.59 (2H, s, H-18)；13C NMR(75MHz,CDCl3)δ:
133.98(C-19),104.00(C-4),102.09(C-12),87.85(C-5),81.05(C-6),64.78(C-16),52.51
(C-17),51.86(C-1),44.34(C-7),37.29(C-11),36.36(C-10),34.59(C-3),30.84(C-9),
29.88(C-18),26.15(C-8),24.64(C-15),24.43(C-2),20.35(C-14),13.01(C-13).HR MS:
C20H31N3O5[M+Na]+Calculated value 416.2156, measured value 416.2155.
4b-2:m.p.:100.8-102.4℃； 1H NMR(300MHz,
CDCl3) δ: 0.94 (3H, d, J=7.2Hz, H-14), 0.96 (3H, d, J=6.1Hz, H-13), 1.43 (3H, s, H-15),
1.21-2.25 (12H, m, H-2, H-3, H-7~H-10 and H-17), 2.28-2.43 (1H, m, H-1), 2.65 (1H, m, H-
11),3.31-3.43(1H,m,H-16),3.83-3.94(1H,m,H-16),4.46-4.52(2H,m,H-17),4.78(1H,d,
J=3.2Hz, H-12), 5.40 (1H, s, H-5), 7.56 (1H, s, H-18), 7.72 (1H, s, H-19)；13C NMR(75MHz,
CDCl3)δ:133.77(C-20),123.48(C-19),104.10(C-4),102.04(C-12),87.84(C-5),80.94
(C-6),64.52(C-16),52.41(C-1),47.19(C-17),44.18(C-7),37.34(C-11),36.27(C-10),
34.46(C-3),30.75(C-9),30.41(C-18),26.08(C-8),24.56(C-15),24.45(C-2),20.31(C-
14),13.04(C-13).HR MS:C20H31N3O5[M+Na]+Calculated value 416.2156, measured value 416.2157.
4b-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.92-0.97 (6H, m, H-14 and H-13), 1.43 (3H, s, H-15), 1.19-2.08 (10H, m, H-2, H-3, H-7~H-
10),2.16-2.19(2H,m,H-17),2.32-2.36(1H,m,H-1),2.64-2.67(1H,m,H-11),3.32-3.40
(1H, m, H-16), 3.84-3.91 (1H, m, H-16), 4.28 (2H, t, J=6.9Hz, H-18), 4.77 (1H, s, H-12),
5.39(1H,s,H-5),7.96(1H,s,H-20),8.09(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:151.9(C-
20),143.0(19),104.1(C-4),102.0(C-12),87.8(C-5),80.9(C-6),64.5(C-16),52.4(C-
1),46.7(C-18),44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),30.7(C-9),29.9(C-18),
26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C20H31N3O5[M+Na]+Meter
Calculation value 416.2156, measured value 416.2155.
4b-4: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.93 (3H, d, J=7.4Hz, H-14), 0.96 (3H, d, J=5.1Hz, H-13), 1.43 (3H, s, H-15), 1.25-2.15
(12H, m, H-2, H-3, H-7~H-10 and H-17), 2.37 (1H, td, J=14.0,3.8Hz, H-1), 2.62-2.71
(1H,m,H-11),3.55-3.62(1H,m,H-16),3.84-3.92(1H,m,H-16),3.97-4.08(2H,m,H-18),
4.81 (1H, d, J=3.3Hz, H-12), 5.44 (1H, s, H-5), 7.65 (1H, s, H-19)；13C NMR(75MHz,CDCl3)δ:
153.99,142.09,104.21,101.97,87.84,80.88,64.67,52.43,46.28,44.22,37.41,36.26,
34.45,30.77,29.32,26.04,24.59,24.46,20.28,13.06.HR MS:C20H32N4O5[M+Na]+Calculated value
431.2265 measured value 431.2266.
4b-5: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.91 (3H, d, J=7.4Hz, H-14), 0.94 (3H, d, J=6.3Hz, H-13), 1.41 (3H, s, H-15), 1.21-2.09
(12H, m, H-2, H-3, H-7~H-10 and H-17), 2.37 (1H, td, J=14.1,3.6Hz, H-1), 2.54-2.69
(1H, m, H-11), 3.23 (2H, t, J=5.8Hz, H-18), 3.66-3.82 (1H, m, H-16), 3.98-4.06 (1H, m, H-
16), 4.80 (1H, d, J=3.2Hz, H-12), 5.44 (2H, s, H-21), 5.57 (1H, s, H-5)；13C NMR(75MHz,
CDCl3)δ:163.55,148.20,104.21,101.97,87.93,80.93,64.67,52.43,44.22,37.40,
36.31,34.50,30.87,29.65,26.11,24.59,24.46,20.31,13.06.HR MS:C20H32N4O5S[M+Na]+
Calculated value 463.1986, measured value 463.1986.
4b-6: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.94 (3H, d, J=7.5Hz, H-13), 0.97 (3H, d, J=6.9Hz, H-14), 1.42 (3H, s, H-15), 1.21-2.06
(10H, m, H-2, H-3, H-7~H-10), 2.31-2.44 (3H, m, H-1 and H-17), 2.60-2.70 (1H, m, H-11),
3.37-3.45(1H,m,H-16),3.86-3.93(1H,m,H-16),4.79-4.87(3H,m,H-12 and H-18),5.50
(1H,s,H-5),7.37-7.41(2H,m,H-21),7.84-7.88(2H,m,H-20)；13C NMR(75MHz,CDCl3)δ:
144.3(C-19),126.3(C-21),117.9(C-20),104.0(C-4),102.1(C-12),87.9(C-5),81.1(C-
6),64.8(C-16),53.7(C-18),52.6(C-1),44.4(C-7),37.3(C-11),36.4(C-10),34.6(C-3),
30.7(C-9),26.2(C-8),24.7(C-15),24.5(C-2),22.7(C-17),20.4(C-14),13.0(C-13).HR
MS:C24H33N3O5[M+Na]+Calculated value 466.2312, measured value 466.2309.
4b-7: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.95-0.98 (6H, m, H-13 and H-14), 1.43 (3H, s, H-15), 1.26-2.09 (10H, m, H-2, H-3, H-7~H-
10),2.28-2.42(3H,m,H-1 and H-17),2.65-2.70(1H,m,H-11),3.41-3.48(1H,m,H-16),
3.88-3.95 (1H, m, H-16), 4.72-4.78 (2H, m, H-18), 4.81 (1H, d, J=3.3Hz, H-12), 5.44 (3H, s,
), H-5 7.38 (1H, t, J=7.5Hz, H-21), 7.46-7.55 (2H, m, H-22 and H-23), 8.08 (1H, d, J=
7.8Hz,H-20)；13C NMR(75MHz,CDCl3)δ:145.9(C-19),133.0(C-24),127.3(C-21),123.9(C-
22),120.0(C-20),109.2(C-23),104.2(C-4),102.1(C-12),87.9(C-5),81.0(C-6),64.8
(C-16),52.5(C-1),45.3(C-18),44.3(C-7),37.4(C-11),36.3(C-10),34.6(C-3),30.6(C-
9),29.9(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.1(C-13).HR MS:
C24H33N3O5[M+Na]+Calculated value 466.2312, measured value 466.2310.
4b-8:m.p.:106.3-108.1℃； 1H NMR(300MHz,
CDCl3) δ: 0.88 (3H, d, J=9.3Hz, H-14), 0.93 (3H, d, J=7.2Hz, H-13), 1.45 (3H, s, H-15),
1.22-2.03 (10H, m, H-2, H-3, H-7~H-10), 2.13-2.17 (2H, m, H-17), 2.32-2.42 (H, m, H-1),
2.64-2.71 (H, m, H-11), 3.62-3.67 (1H, m, H-16), 4.10~4.18 (1H, m, H-16), 4.66 (2H, t, J=
6.0Hz, H-18), 4.85 (1H, s, H-12), 5.43 (1H, s, H-5), 7.40 (1H, t, J=7.2Hz, H-21), 7.52 (1H,
T, J=7.2Hz, H-22), 7.59 (1H, d, J=7.8Hz, H-23), 8.02 (1H, d, J=8.7Hz, H-20)；13C NMR
(75MHz,CDCl3)δ:143.5(C-24),127.9(C-19),127.3(C-20),124.5(C-22),120.3(C-21),
108.5(C-23),104.1(C-4),102.1(C-12),87.9(C-5),81.0(C-6),77.4(C-18),64.1(C-16),
52.5(C-1),44.3(C-7),37.3(C-11),36.4(C-10),34.5(C-3),30.8(C-9),28.6(C-17),26.1
(C-8),24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C24H33N3O6[M+Na]+Calculated value
482.2262 measured value 482.2260.
5a-1:m.p.:135.2-136.5℃； 1H NMR(300MHz,
CDCl3) δ: 0.72 (3H, d, J=7.8Hz, H-13), 0.95 (3H, d, J=5.1Hz, H-14), 1.43 (3H, s, H-15),
1.25-2.06 (10H, m, H-2, H-3, H-7~H-10), 2.31-2.40 (1H, m, H-1), 2.63-2.65 (1H, m, H-11),
3.80-3.86 (1H, m, H-16), 4.28-4.35 (1H, m, H-16), 4.63 (2H, t, J=4.8Hz, H-18), 4.79 (1H, s,
H-12),5.19(1H,s,H-5),8.64(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:143.0(C-18),104.2
(C-4),102.3(C-12),87.9(C-5),80.7(C-6),65.7(C-16),52.3(C-1),48.4(C-17),43.9(C-
7),37.3(C-11),36.3(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.5(C-15),24.3(C-2),
20.3(C-14),12.8(C-13).HR MS:C18H28N4O5[M+Na]+Calculated value 403.1952, measured value 403.1951.
5a-2:m.p.:123.2-124.6℃； 1H NMR(300MHz,
CDCl3) δ: 0.72 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=4.8Hz, H-14), 1.43 (3H, s, H-15),
1.24-2.05 (10H, m, H-2, H-3, H-7~H-10), 2.31-2.39 (1H, m, H-1), 2.54-2.61 (1H, m, H-11),
3.96-4.03 (1H, m, H-16), 4.38-4.45 (1H, m, H-16), 4.78 (1H, s, H-12), 4.87 (2H, t, J=4.8Hz,
H-17),5.22(1H,s,H-5),8.52(1H,s,H-18)；13C NMR(75MHz,CDCl3)δ:152.8(C-18),104.1
(C-4),102.2(C-12),87.9(C-5),80.9(C-6),65.5(C-16),53.1(C-17),52.4(C-1),44.1(C-
7),37.3(C-11),36.3(C-10),34.4(C-3),30.6(C-9),26.1(C-8),24.6(C-15),24.0(C-2),
20.3(C-14),12.6(C-13).HR MS:C18H28N4O5[M+Na]+Calculated value 403.1952, measured value 403.1949.
5a-3:m.p.:117.4-119.1℃； 1H NMR(300MHz,
CDCl3) δ: 0.93 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=5.7Hz, H-13), 1.43 (3H, s, H-15),
1.26-2.07 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.42 (1H, m, H-1), 2.56 (1H, s, H-20), 2.62-
2.73(1H,m,H-11),3.41-3.49(1H,m,H-16),3.87-3.94(1H,m,H-16),4.33-4.38(2H,m,H-
18),4.80(1H,s,H-12),5.40(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:162.75,103.96,102.03,
87.79,80.89,64.22,52.46,49.83,44.24,37.22,36.29,34.53,30.73,26.03,24.58,
24.39,20.27,12.90,10.76.HR MS:C19H30N4O5[M+Na]+Calculated value 417.2108, measured value 417.2106.
5a-4:m.p.:114.2-115.7℃； 1H NMR(300MHz,
CDCl3) δ: 0.75 (3H, d, J=7.2Hz, H-14), 0.94 (3H, d, J=4.5Hz, H-13), 1.42 (3H, s, H-15),
1.21-2.04 (10H, m, H-2, H-3, H-7~H-10), 2.29-2.38 (1H, m, H-1), 2.57 (3H, s, H-19), 2.58-
2.61(1H,m,H-11),3.80-3.87(1H,m,H-16),4.34-4.37(1H,m,H-16),4.46-4.48(2H,m,H-
17),4.76(1H,s,H-12),5.11(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:152.1(C-18),104.2(C-
4),102.3(C-12),87.7(C-5),80.7(C-6),65.8(C-16),52.3(C-1),47.0(C-17),43.9(C-7),
37.2(C-11),36.2(C-10),34.3(C-3),30.5(C-9),26.0(C-8),24.5(C-15),24.2(C-2),20.3
(C-14),13.0(C-13),8.9(C-19).HR MS:C19H30N4O5[M+Na]+Calculated value 417.2108, measured value
417.2106.
5a-5:m.p.:121.7-123.3℃； 1H NMR(300MHz,
CDCl3) δ: 0.90 (3H, d, J=7.5Hz, H-14), 0.96 (3H, d, J=6.3Hz, H-13), 1.43 (3H, s, H-15),
1.21-2.04 (10H, m, H-2, H-3, H-7~H-10), 2.32-2.43 (H, m, H-1), 2.61-2.66 (H, m, H-11),
3.63 (2H, t, J=5.7Hz, H-17), 3.75-3.83 (1H, m, H-16), 3.93 (3H, s, H-19), 4.12-4.19 (H, m,
), H-16 4.83 (1H, d, J=2.7Hz, H-12), 5.43 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:154.0(C-
18),104.1(C-4),102.2(C-12),87.9(C-5),80.9(C-6),66.5(C-16),52.4(C-1),44.2(C-
7),37.4(C-11),36.3(C-10),34.5(C-3),33.6(C-17),33.4(C-19),30.7(C-9),26.1(C-8),
24.6(C-15),24.3(C-2),20.3(C-14),12.9(C-13).HR MS:C19H30N4O5S[M+Na]+Calculated value
449.1829 measured value 449.1821.
5a-6:m.p.:129.8-130.8℃； 1H NMR(300MHz,
CDCl3) δ: 0.87 (3H, d, J=6.9Hz, H-13), 0.98 (3H, d, J=7.5Hz, H-14), 1.44 (3H, s, H-15),
1.26-2.12 (10H, m, H-2, H-3, H-7~H-10), 2.33-2.43 (1H, m, H-1), 2.68-2.71 (1H, m, H-11),
3.94-4.00 (1H, m, H-16), 4.52-4.59 (1H, m, H-16), 4.78-4.82 (1H, m, H-17), 4.83 (1H, d, J=
2.7Hz,H-12),4.91-4.99(1H,m,H-17),5.15(1H,s,H-5),7.47-7.50(3H,m,H-21 and H-
22), 8.17 (1H, d, J=5.4Hz, H-20)；13C NMR(75MHz,CDCl3)δ:165.1(C-18),130.3(C-22),
128.8(C-21),127.3(C-19),126.7(C-20),104.0(C-4),102.0(C-12),87.8(C-5),80.8(C-
6),64.9(C-16),52.1(C-1),52.3(C-17),44.0(C-7),37.1(C-11),36.3(C-10),34.2(C-3),
30.6(C-9),26.1(C-8),24.4(C-15),24.0(C-2),20.0(C-14),12.87(C-13).HR MS:
C24H32N4O5[M+Na]+Calculated value 479.2265, measured value 479.2268.
5b-1: yellow oil； 1H NMR(300MHz,CDCl3)δ:0.94
(3H, d, J=7.8Hz, H-13), 0.97 (3H, d, J=6.6Hz, H-14), 1.44 (3H, s, H-15), 1.26-2.06 (10H,
M, H-2, H-3, H-7~H-10), 2.22-2.28 (2H, m, H-17), 2.33-2.42 (1H, m, H-1), 2.63-2.70 (1H, m,
), H-11 3.39-3.46 (1H, m, H-16), 3.87-3.94 (1H, m, H-16), 4.54 (2H, t, J=6.9Hz, H-18), 4.79
(H,s,H-12),5.39(1H,s,H-5),8.62(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:142.6(C-19),
104.2(C-4),102.2(C-12),87.9(C-5),80.9(C-6),64.3(C-16),52.4(C-1),45.5(C-18),
44.2(C-7),37.4(C-11),36.3(C-10),34.5(C-3),30.7(C-9),30.0(C-17),26.1(C-8),24.6
(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C19H30N4O5[M+Na]+Calculated value 417.2108 is surveyed
Definite value 417.2111.
5b-2: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.93-0.98 (6H, m, H-13 and H-14), 1.43 (3H, s, H-15), 1.26-2.06 (10H, m, H-2, H-3, H-7~H-
10),2.28-2.32(2H,m,H-17),2.37-2.43(1H,m,H-1),2.61-2.68(1H,m,H-11),3.35-3.42
(1H,m,H-16),3.86-3.92(1H,m,H-16),4.74-4.79(3H,m,H-12 and H-18),5.41(1H,s,H-
5),8.51(1H,s,H-19)；13C NMR(75MHz,CDCl3)δ:152.8(C-19),104.1(C-4),102.2(C-12),
87.9(C-5),81.0(C-6),64.4(C-16),52.5(C-1),50.2(C-18),44.3(C-7),37.4(C-11),36.4
(C-10),34.6(C-3),30.8(C-9),29.5(C-17),26.1(C-8),24.6(C-15),24.5(C-2),20.3(C-
14),13.0(C-13).HR MS:C19H30N4O5[M+Na]+Calculated value 417.2108, measured value 417.2114.
5b-3: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.93 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=5.7Hz, H-13), 1.43 (3H, s, H-15), 1.26-2.07
(10H, m, H-2, H-3, H-7~H-10), 2.16-2.22 (2H, m, H-17), 2.32-2.42 (1H, m, H-1), 2.56 (1H, s,
H-20),2.62-2.73(1H,m,H-11),3.41-3.49(1H,m,H-16),3.87-3.94(1H,m,H-16),4.33-
4.38(2H,m,H-18),4.80(1H,s,H-12),5.40(1H,s,H-5)；13C NMR(75MHz,CDCl3)δ:162.75(C-
19),103.96(C-4),102.03(C-12),87.79(C-5),80.89(C-6),64.22(C-16),52.46(C-1),
49.83(C-18),44.24(C-7),37.22(C-11),36.29(C-10),34.53(C-3),30.73(C-9),29.38(C-
17),26.03(C-8),24.58(C-15),24.39(C-2),20.27(C-14),12.90(C-13),10.76(C-20).HR
MS:C20H32N4O5[M+Na]+Calculated value 431.2265, measured value 431.2272.
5b-4: yellow oil； 1H NMR(300MHz,CDCl3)δ:
0.93 (3H, d, J=7.5Hz, H-13), 0.97 (3H, d, J=6.1Hz, H-13), 1.44 (3H, s, H-15), 1.19-2.10
(10H, m, H-2, H-3, H-7~H-10), 2.14-2.27 (2H, m, H-17), 2.32-2.47 (1H, m, H-1), 2.57 (3H, s,
H-20),2.64-2.73(1H,m,H-11),3.39-3.59(1H,m,H-16),3.88-3.95(1H,m,H-16),4.33-
4.43 (2H, m, H-18), 4.81 (1H, d, J=3.3Hz, H-12), 5.41 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:
104.16(C-4),102.01(C-12),87.87(C-5),80.86(C-6),64.31(C-16),52.42(C-1),44.27
(C-18),44.17(C-7),37.41(C-11),36.30(C-10),34.48(C-3),30.71(C-9),29.72(C-17),
26.04(C-8),24.59(C-15),24.48(C-2),20.26(C-14),12.99(C-13),8.70(C-20).HR MS:
C20H32N4O5[M+Na]+Calculated value 431.2265, measured value 431.2273.
5b-5: yellow slurry； 1H NMR(300MHz,CDCl3)δ:
0.91 (3H, d, J=7.5Hz, H-13), 0.95 (3H, d, J=6.3Hz, H-13), 1.43 (3H, s, H-15), 1.25-2.06
(12H, m, H-2, H-3, H-7~H-10 and H-17), 2.32-2.41 (1H, m, H-1), 2.62-2.67 (1H, m, H-11),
3.42-3.55(3H,m,H-16 and H-18),3.92(1H,s,H-20),3.97-4.04(1H,m,H-16),4.80(1H,d,
J=3.0Hz, H-12), 5.39 (1H, s, H-5)；13C NMR(75MHz,CDCl3)δ:154.2(C-19),104.1(C-4),
102.1(C-12),87.9(C-5),81.0(C-6),66.0(C-16),52.4(C-1),44.2(C-7),37.4(C-11),
36.3(C-10),34.5(C-3),33.3(C-18),30.8(C-9),30.3(C-17),29.1(C-20),26.1(C-8),
24.6(C-15),24.5(C-2),20.3(C-14),13.0(C-13).HR MS:C20H32N4O5S[M+Na]+Calculated value
463.1986 measured value 463.1985.
5b-6: white slurry object； 1H NMR(300MHz,CDCl3)δ:
0.87 (3H, d, J=7.2Hz, H-13) .0.96 (3H, d, J=6.7Hz, H-14), 1.43 (3H, s, H-15), 1.12-2.11
(10H, m, H-2, H-3, H-7~H-10), 2.31-2.37 (3H, m, H-1, H-17), 2.62-2.72 (1H, m, H-11), 3.36-
3.54 (1H, m, H-16), 3.97-4.01 (1H, m, H-16), 4.73-4.81 (2H, m, H-18), 4.82 (1H, d, J=2.7Hz,
), H-12 5.46 (1H, s, H-5), 7.42-7.58 (3H, m, H-22 and H-23), 8.27-8.07 (2H, d, J=5.4Hz, H-
21)；13C NMR(75MHz,CDCl3)δ:165.11(C-19),130.21(C-23),128.80(C-22),127.40(C-20),
126.81(C-21),104.07(C-4),102.21(C-12),87.87(C-5),80.98(C-6),64.51(C-16),52.52
(C-1),50.28(C-17),44.31(C-7),37.37(C-11),36.37(C-10),34.55(C-3),30.82(C-9),
29.67(C-18),26.12(C-8),24.61(C-15),24.53(C-2),20.31(C-14),12.99(C-13).HR MS:
C25H34N4O5[M+Na]+Calculated value 493.2427, measured value 493.2421.
The anti-angiogenesis activity of embodiment 3, DHA amine derivant and DHA azole derivative is tested
The anti-angiogenesis activity of DHA amine derivant and DHA azole derivative entrusts Lilly Co., Eli. Open
Innovation Drug Discovery (OIDD) program is tested, and carries out single concentration primary dcreening operation (Primary first
SP), more concentration determinations (Primary CRC) then are carried out to the potentiality molecule that preliminary screening goes out.It the results are shown in Table 5.
5 anti-angiogenesis activity test result of table
As can be seen from Table 5, target compound 1~5 is most of has certain anti-angiogenesis activity, wherein 7 changes
It closes the inhibitory activity of object (1c, 2a-4,2a-5,2b-1,4b-6,4b-8 and 5b-6) under 10 μM of test concentrations and is greater than 50%, change
The inhibitory activity for closing object 2b-1 has been up to 94%；Under 2 μM of test concentrations, compound 1c, 2b-1,4b-6,4b-8,5b-6
Inhibiting rate equally near or above 50%；Particularly, from anti-angiogenesis IC50Value sees that compound 2b-1,4b-8,5b-6 is equal
It is at 2 μM and following.On the whole, DHA amine and azole derivative show very strong anti-angiogenesis activity, can be used as anti-
Angiogenesis drug is further developed.
Finally, it is stated that preferred embodiment above is only used to illustrate the technical scheme of the present invention and not to limit it, although logical
It crosses above preferred embodiment the present invention is described in detail, however, those skilled in the art should understand that, can be
Various changes are made to it in form and in details, without departing from claims of the present invention limited range.
Claims (6)
1. dihydroqinghaosu shown in Formulas I or its raceme, stereoisomer, tautomer, nitrogen oxides, pharmacy
Upper acceptable salt is preparing the application in anti-angiogenic medicaments:
In Formulas I, n is 1 or 2；
Y is-NR1R2、
R1And R2It independently is H, C1-C3 alkyl or C1-C3 hydroxyalkyl；
R3For H, C1-C3 alkyl, C1-C3 hydroxyalkyl, phenyl substituted or unsubstituted, tertbutyloxycarbonyl, benzyloxycarbonyl group or fatty acyl
Base；Substituent group on the phenyl is one or more, is independently selected from halogen, hydroxyl, amino or C1-C3 alkyl；
R4And R5It independently is H or C1-C3 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C3 alkyl；
R8For H, C1-C3 alkyl, C1-C3 alkylthio group, phenyl substituted or unsubstituted；Substituent group on the phenyl is one or more
It is a, it is independently selected from halogen, hydroxyl, amino or C1-C3 alkyl.
2. application as described in claim 1, it is characterised in that: in Formulas I,
R1And R2It independently is H, C1-C2 alkyl or C1-C2 hydroxyalkyl；
R3For H, C1-C2 alkyl, C1-C2 hydroxyalkyl, phenyl substituted or unsubstituted, tertbutyloxycarbonyl, benzyloxycarbonyl group or alkanoyl；
Substituent group on the phenyl is one or more, is independently selected from halogen, hydroxyl, amino or C1-C2 alkyl；
R4And R5It independently is H or C1-C2 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C2 alkyl；
R8For H, C1-C2 alkyl, C1-C2 alkylthio group, phenyl substituted or unsubstituted；Substituent group on the phenyl is one or more
It is a, it is independently selected from halogen, hydroxyl, amino or C1-C2 alkyl.
3. application as claimed in claim 2, it is characterised in that: in Formulas I,
R1And R2It independently is H, C1-C2 alkyl or C1-C2 hydroxyalkyl；
R3For H, C1-C2 alkyl, C1-C2 hydroxyalkyl, phenyl, tertbutyloxycarbonyl, benzyloxycarbonyl group or acetyl group；
R4And R5It independently is H or C1-C2 alkyl；
R6And R7It independently is H, amino, hydroxyl or C1-C2 alkyl；
R8For H, C1-C2 alkyl, C1-C2 alkylthio group or phenyl.
4. application as claimed in claim 3, it is characterised in that: in Formulas I,
R1And R2It independently is H, methyl, ethyl or ethoxy；
R3For H, methyl, ethoxy, phenyl or tertbutyloxycarbonyl；
R4And R5It independently is H or methyl；
R6And R7It independently is H or amino；
R8For H, methyl, methyl mercapto or phenyl.
5. application as claimed in claim 4, it is characterised in that: dihydroqinghaosu shown in Formulas I is following compound
Any one of:
6. application as claimed in claim 5, it is characterised in that: dihydroqinghaosu shown in Formulas I is following compound
Any one of: 1c, 2a-4,2a-5,2b-1,4b-6,4b-8,5b-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910785570.9A CN110448551A (en) | 2019-08-23 | 2019-08-23 | Dihydroqinghaosu is preparing the application in anti-angiogenic medicaments |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910785570.9A CN110448551A (en) | 2019-08-23 | 2019-08-23 | Dihydroqinghaosu is preparing the application in anti-angiogenic medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110448551A true CN110448551A (en) | 2019-11-15 |
Family
ID=68488892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910785570.9A Pending CN110448551A (en) | 2019-08-23 | 2019-08-23 | Dihydroqinghaosu is preparing the application in anti-angiogenic medicaments |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110448551A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (en) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | Artesunate derivative and preparation method and application thereof |
| CN114933603A (en) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | Artemisinin derivative and preparation method and application thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296009A (en) * | 1999-11-12 | 2001-05-23 | 中国科学院上海药物研究所 | Arteannuin derivant containing azacyclic radical and preparation process thereof |
| CN1448138A (en) * | 2003-04-29 | 2003-10-15 | 浙江大学 | Artesunate and dihydroarteannuin medicine preparation for proofing formation of blood vessel and use thereof |
| US20040072896A1 (en) * | 2002-10-15 | 2004-04-15 | Elsohly Mahmoud A. | Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents |
| CN101879158A (en) * | 2010-07-01 | 2010-11-10 | 中国科学院广州生物医药与健康研究院 | New application of artemisinin derivant |
| CN102010422A (en) * | 2010-11-23 | 2011-04-13 | 沈阳药科大学 | Guanidyl-containing artemisinin derivates and application thereof |
| CA2807263A1 (en) * | 2010-08-03 | 2012-02-09 | Dafra Pharma N.V. | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
| CN102675337A (en) * | 2012-05-21 | 2012-09-19 | 中国人民解放军第三军医大学 | Dihydroarteannuin derivatives and application thereof |
| CN103183682A (en) * | 2011-12-31 | 2013-07-03 | 沈阳药科大学 | C-10 site carbamido substituted artemisinin derivative, preparation method and application |
| CN104974171A (en) * | 2015-05-28 | 2015-10-14 | 沈阳药科大学 | Dihydroartemisinin phenyl ether derivatives and applications thereof |
| CN105503898A (en) * | 2015-11-16 | 2016-04-20 | 中国人民解放军第三军医大学 | Nitrogen-heterocycle-containing artemisinin derivative and preparation method thereof |
-
2019
- 2019-08-23 CN CN201910785570.9A patent/CN110448551A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296009A (en) * | 1999-11-12 | 2001-05-23 | 中国科学院上海药物研究所 | Arteannuin derivant containing azacyclic radical and preparation process thereof |
| US20040072896A1 (en) * | 2002-10-15 | 2004-04-15 | Elsohly Mahmoud A. | Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents |
| CN1448138A (en) * | 2003-04-29 | 2003-10-15 | 浙江大学 | Artesunate and dihydroarteannuin medicine preparation for proofing formation of blood vessel and use thereof |
| CN101879158A (en) * | 2010-07-01 | 2010-11-10 | 中国科学院广州生物医药与健康研究院 | New application of artemisinin derivant |
| CA2807263A1 (en) * | 2010-08-03 | 2012-02-09 | Dafra Pharma N.V. | Novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties |
| CN102010422A (en) * | 2010-11-23 | 2011-04-13 | 沈阳药科大学 | Guanidyl-containing artemisinin derivates and application thereof |
| CN103183682A (en) * | 2011-12-31 | 2013-07-03 | 沈阳药科大学 | C-10 site carbamido substituted artemisinin derivative, preparation method and application |
| CN102675337A (en) * | 2012-05-21 | 2012-09-19 | 中国人民解放军第三军医大学 | Dihydroarteannuin derivatives and application thereof |
| CN104974171A (en) * | 2015-05-28 | 2015-10-14 | 沈阳药科大学 | Dihydroartemisinin phenyl ether derivatives and applications thereof |
| CN105503898A (en) * | 2015-11-16 | 2016-04-20 | 中国人民解放军第三军医大学 | Nitrogen-heterocycle-containing artemisinin derivative and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| CHONG WU，等: "Design, Synthesis and Evaluation of the Antibacterial Enhancement Activities of Amino Dihydroartemisinin Derivatives", 《MOLECULES》, vol. 18, 31 December 2013 (2013-12-31), pages 6869 * |
| MORAKE, MOKHITLI，等: "Preliminary Evaluation of Artemisinin-Cholesterol Conjugates as Potential Drugs for the Treatment of Intractable Forms of Malaria and Tuberculosis", 《CHEMMEDCHEM》, vol. 13, no. 1, 31 January 2018 (2018-01-31), pages 4, XP055753068, DOI: 10.1002/cmdc.201700579 * |
| SOOMRO, SHAHID，等: "Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties", 《JOURNAL OF CELLULAR AND MOLECULAR MEDICINE》, vol. 15, no. 5, 31 May 2011 (2011-05-31), pages 1123 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114014872A (en) * | 2021-11-29 | 2022-02-08 | 桂林医学院 | Artesunate derivative and preparation method and application thereof |
| CN114933603A (en) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | Artemisinin derivative and preparation method and application thereof |
| WO2023236485A1 (en) * | 2022-06-10 | 2023-12-14 | 上海英诺富成生物科技有限公司 | Artemisinin derivatives, preparation method therefor, and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110448552A (en) | Dihydroqinghaosu is preparing the application in antimalarial agent | |
| ES2911449T3 (en) | Dihydropyrimidinoisoquinolinones and their pharmaceutical compositions for the treatment of multiple sclerosis | |
| ES2777123T3 (en) | Pyrazole for the treatment of autoimmune disorders | |
| BR112018067392A2 (en) | wdr5 protein binding inhibitors | |
| BR112019013017A2 (en) | tenofovir antiviral aliphatic ester compounds or pharmaceutically acceptable salts thereof, pharmaceutical composition and use thereof | |
| CN107074827B (en) | Pladienolide pyridine compounds and methods of use | |
| BR112021007044B1 (en) | Hemoglobin modulating compounds, their compositions and their uses | |
| CN110448551A (en) | Dihydroqinghaosu is preparing the application in anti-angiogenic medicaments | |
| BR112013013127B1 (en) | PROCESS FOR THE PREPARATION OF MORFOLINIL ANTHRACYCLINE DERIVATIVES, MORFOLINIL ANTHRACYCLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | |
| EP2935262A1 (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) | |
| AU2016357433B2 (en) | A solid state form of pladienolide pyridine compounds and methods of use | |
| BRPI0906359A2 (en) | substituted heteroarylamide diazepinopyrimidone derivatives | |
| CN105111201B (en) | 5-methyl-2-(pyridinyl-2-amino)-8H-pyrido[2,3-d]pyrimidin-7-ketone compounds | |
| CN113912663B (en) | Betulinic acid derivative, preparation method, pharmaceutical composition and application thereof | |
| CN110496121A (en) | Dihydroqinghaosu resists the application in leishmanial drug in preparation | |
| CA2968455A1 (en) | Antibacterial compounds having broad spectrum of activity | |
| CN110403933A (en) | Dihydroqinghaosu application in preparation of anti-tumor drugs | |
| CN113874354B (en) | Pyridone derivative, preparation method thereof and application thereof in medicine | |
| CA3152167A1 (en) | Irak inhibitor and preparation method therefor and use thereof | |
| CN112979654A (en) | Heteroaryl fused ring compound, preparation method and application thereof | |
| CN111630047B (en) | Benzazepine compounds containing carboxylic acid groups, and preparation method and application thereof | |
| CA3213573A1 (en) | Preparation method for bicyclic compound and application as antifungal agent | |
| CN113754680A (en) | Alpha fluoroacyl piperazine derivative and preparation and application thereof | |
| CN110368383A (en) | Dihydroqinghaosu is preparing the application in blood lipid-lowering medicine | |
| CA3010462A1 (en) | Uridine phosphoramide prodrug, preparation method therefor, and medicinal uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191115 |
|
| RJ01 | Rejection of invention patent application after publication |